[Press release] ViiV Healthcare | Tivicay and Dovato receive positive CHMP opinion for young children living with HIV

Back to the "HIV and Co-Infections News" list

ViiV Healthcare’s Tivicay and Dovato receive positive CHMP opinion for young children living with HIV, advancing efforts to close paediatric treatment gaps in the EU

Tags:

ViiV Healthcare press release

London, 16 November 2026 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Tivicay (dolutegravir [DTG]) and Dovato (dolutegravir/lamivudine [DTG/3TC]) to extend their use to eligible younger age groups.

The CHMP has recommended approval for an extension to the existing dispersible tablet indication for DTG in combination with other antiretroviral medicinal products for the treatment of HIV infected adults, adolescents, children and term neonates from birth and weighing at least 2 kg.

The CHMP has also recommended the approval of DTG/3TC, a single-tablet, two-drug regimen as a new dispersible tablet formulation for the treatment of HIV-1 infection in children at least 3 months of age, weighing at least 6 kg to less than 25 kg. In addition, the CHMP has recommended approval for an extension to the existing film-coated tablet indication for DTG/3TC, for the treatment of HIV-1 infection in children weighing at least 20 kg. Both recommendations apply to patients with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

Read the full press release here.

 

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.